DE2357800A1 - Verfahren zur herstellung von gammaglobulin - Google Patents
Verfahren zur herstellung von gammaglobulinInfo
- Publication number
- DE2357800A1 DE2357800A1 DE2357800A DE2357800A DE2357800A1 DE 2357800 A1 DE2357800 A1 DE 2357800A1 DE 2357800 A DE2357800 A DE 2357800A DE 2357800 A DE2357800 A DE 2357800A DE 2357800 A1 DE2357800 A1 DE 2357800A1
- Authority
- DE
- Germany
- Prior art keywords
- block copolymer
- globulin
- preserving
- subsequent stage
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 108010074605 gamma-Globulins Proteins 0.000 title 1
- 229920001400 block copolymer Polymers 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 239000002504 physiological saline solution Substances 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 8
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 8
- 239000003114 blood coagulation factor Substances 0.000 claims description 8
- -1 polyoxypropylene Polymers 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 description 17
- 108010044091 Globulins Proteins 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000005194 fractionation Methods 0.000 description 15
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 229920001983 poloxamer Polymers 0.000 description 9
- 230000000717 retained effect Effects 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108010032597 Cohn fraction II Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010045362 Serum Globulins Proteins 0.000 description 2
- 102000005686 Serum Globulins Human genes 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QMHLJNFGMZBHIP-UHFFFAOYSA-N oxirane;propane-1,2-diol Chemical compound C1CO1.CC(O)CO QMHLJNFGMZBHIP-UHFFFAOYSA-N 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 108010044316 Cohn fraction III Proteins 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229910000154 gallium phosphate Inorganic materials 0.000 description 1
- LWFNJDOYCSNXDO-UHFFFAOYSA-K gallium;phosphate Chemical compound [Ga+3].[O-]P([O-])([O-])=O LWFNJDOYCSNXDO-UHFFFAOYSA-K 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- XWKBMOUUGHARTI-UHFFFAOYSA-N tricalcium;diphosphite Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])[O-].[O-]P([O-])[O-] XWKBMOUUGHARTI-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30984172A | 1972-11-27 | 1972-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2357800A1 true DE2357800A1 (de) | 1974-06-06 |
Family
ID=23199896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2357800A Ceased DE2357800A1 (de) | 1972-11-27 | 1973-11-20 | Verfahren zur herstellung von gammaglobulin |
Country Status (16)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4124576A (en) | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2364792A1 (de) * | 1973-01-15 | 1974-07-18 | South African Inventions | Verfahren zum reinigen von gammaglobulin |
| DE2500076C3 (de) * | 1975-01-02 | 1982-11-18 | SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld | Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen |
| US4057628A (en) * | 1976-04-19 | 1977-11-08 | William L. Wilson | Removal of hepatitis associated antigen from plasma |
| JPS6016406B2 (ja) * | 1976-08-06 | 1985-04-25 | マイヤ−、ル−イス、コ−バル | 静脈内に投与可能なガンマ・グロブリンの製造法ならびにそれにより調製したガンマ・グロブリン |
| JPS5347515A (en) * | 1976-10-13 | 1978-04-28 | Green Cross Corp:The | Gamma-globulin pharmaceutical preparation for intravenous injection |
| US4272521A (en) * | 1979-07-16 | 1981-06-09 | Cutter Laboratories, Inc. | Purified immune serum globulin |
| JPS5732228A (en) * | 1980-08-05 | 1982-02-20 | Green Cross Corp:The | Preparation of immunoglobulin usable for intravenous injection |
| EP0078331B1 (en) * | 1981-10-29 | 1986-01-29 | Green Cross Corporation | Process for preparing immunoglobulin suitable for intravenous injection |
| JPS58180433A (ja) * | 1982-04-16 | 1983-10-21 | Fujirebio Inc | 免疫グロブリンから抗補体作用物質の除去法 |
-
1973
- 1973-11-16 ZA ZA738779A patent/ZA738779B/xx unknown
- 1973-11-16 IL IL43643A patent/IL43643A/en unknown
- 1973-11-19 AU AU62658/73A patent/AU6265873A/en not_active Expired
- 1973-11-20 BE BE137926A patent/BE807527A/xx unknown
- 1973-11-20 NL NL7315859A patent/NL7315859A/xx not_active Application Discontinuation
- 1973-11-20 DE DE2357800A patent/DE2357800A1/de not_active Ceased
- 1973-11-21 IT IT31571/73A patent/IT1196391B/it active
- 1973-11-23 DK DK635573AA patent/DK135270B/da unknown
- 1973-11-26 NO NO4490/73A patent/NO137861C/no unknown
- 1973-11-26 FR FR7341980A patent/FR2207698B1/fr not_active Expired
- 1973-11-26 SE SE7315988A patent/SE390795B/xx unknown
- 1973-11-26 ES ES420846A patent/ES420846A1/es not_active Expired
- 1973-11-26 GB GB5470373A patent/GB1435816A/en not_active Expired
- 1973-11-26 JP JP48132524A patent/JPS5843371B2/ja not_active Expired
- 1973-11-26 AT AT987973A patent/AT325208B/de not_active IP Right Cessation
- 1973-11-26 CA CA186,705A patent/CA1016069A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4124576A (en) | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS4981519A (enrdf_load_stackoverflow) | 1974-08-06 |
| FR2207698B1 (enrdf_load_stackoverflow) | 1976-09-03 |
| ES420846A1 (es) | 1976-06-16 |
| FR2207698A1 (enrdf_load_stackoverflow) | 1974-06-21 |
| JPS5843371B2 (ja) | 1983-09-27 |
| SE390795B (sv) | 1977-01-24 |
| IL43643A0 (en) | 1974-03-14 |
| BE807527A (fr) | 1974-03-15 |
| CA1016069A (en) | 1977-08-23 |
| AT325208B (de) | 1975-10-10 |
| DK135270C (enrdf_load_stackoverflow) | 1977-09-19 |
| NL7315859A (enrdf_load_stackoverflow) | 1974-05-29 |
| NO137861C (no) | 1978-05-10 |
| DK135270B (da) | 1977-03-28 |
| NO137861B (no) | 1978-03-30 |
| AU6265873A (en) | 1975-05-22 |
| IT1196391B (it) | 1988-11-16 |
| IL43643A (en) | 1976-10-31 |
| GB1435816A (en) | 1976-05-19 |
| ZA738779B (en) | 1974-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2029455C3 (de) | Verfahren zur Herstellung eines neuen Prothrombinkomplexes | |
| DE2324717C3 (de) | Verfahren zur Herstellung eines stabilen AHF-Konzentrates (Faktor VIII) | |
| DE2333883C3 (de) | Verfahren zur Herstellung von hochgereinigtem Humanalbumin | |
| DE2936047A1 (de) | Verfahren zur herstellung eines intravenoes verabreichbaren antikoerperhaeltigen immunglobulinpraeparates und danach hergestellte praeparate | |
| DE3129987C2 (de) | Verfahren zur Herstellung eines Faktor VIII(AHF)-Hochkonzentrates | |
| DE2725711A1 (de) | Verfahren zur herstellung von antithrombin iii | |
| DE2357800A1 (de) | Verfahren zur herstellung von gammaglobulin | |
| DE2127159A1 (de) | Verfahren zur Fraktionierung von Plasmaproteinen | |
| DE2818922A1 (de) | Verbesserte impfstoffe mit gehalt an kapselpolysacchariden | |
| DE3686390T2 (de) | Verfahren zur herstellung vom antihaemophilfaktor (ahf) durch kaeltefaellung und zur verbesserung der loeslichkeit des hergestellten ahf-produktes. | |
| DE2403994A1 (de) | Herstellung von antisera | |
| CH628246A5 (de) | Verfahren zur herstellung eines schuetzenden pertussis-antigens. | |
| DE2833545A1 (de) | Hochmolekulare meningokokken- gruppe c-vaccine und verfahren zu ihrer herstellung | |
| DE2837168A1 (de) | Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten immunglobulinloesung | |
| DE3236126A1 (de) | Verfahren zur herstellung von zur intravenoesen verabreichung geeignetem (gamma)-globulin | |
| DE2713817A1 (de) | Verfahren zum gewinnen von immunglobulin | |
| DE1642676A1 (de) | Verfahren zur Reinigung von Lipopolysacchariden | |
| CH641353A5 (de) | Kohlenhydrathaltige sterile waessrige loesung zur parenteralen verabreichung. | |
| DE2515666C3 (de) | Piasminreiche Gammaglobulinfraktion, Verfahren zu deren Herstellung und das Verfahrensprodukt enthaltendes Gammaglobulinpräparat | |
| DE3101001A1 (de) | Verfahren zur konzentration und reinigung des antihaemophilie-faktors oder faktor viii | |
| DE1818054C2 (de) | Verfahren zur Gewinnung von cytobiotischen Globulinen | |
| DE1949314A1 (de) | Prothrombinkomplex und Verfahren zu dessen Herstellung | |
| DE1617344A1 (de) | Verfahren zur Herstellung einer Tetanus-Vaccine | |
| DE1667929A1 (de) | Vakzine | |
| DE2214260A1 (de) | Verfahren zum Abtrennen von Fallungen bildenden Proteinen aus Serum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8131 | Rejection |